Achieve Life Sciences ACHV Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Comfort Systems USAFIX

$232K+37.3%

MicroStrategyMSTR

$6.52M+7.7%

Cloudflare, Inc.NET

$2.43M+145%

Realty IncomeO

$8.82M+49.0%

NXP SemiconductorsNXPI

$2M+100%

Ubiquiti Inc.UI

$321K-1.2%

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Achieve Life Sciences's amortization expense related to capitalized debt issuance costs?: Achieve Life Sciences (ACHV) reported amortization expense related to capitalized debt issuance costs of $12K in Q1 2026.
How has Achieve Life Sciences's amortization expense related to capitalized debt issuance costs changed year-over-year?: Achieve Life Sciences's amortization expense related to capitalized debt issuance costs decreased by 14.3% year-over-year, from $14K to $12K.